ORLANDO, FLORIDA / ACCESS Newswire / September 19, 2025 / RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (Nasdaq:ENLV) and 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV this Saturday, September 20, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
Access the interviews in their entirety at:
In an exclusive interview, Dr. Oren Hershkovitz, Chief Executive Officer of Enlivex Therapeutics, will appear on the RedChip Small Stocks Big Money™ show on Bloomberg TV to discuss the company’s recently announced positive Phase IIa topline results for Allocetra™ in knee osteoarthritis (KOA). Dr. Hershkovitz will share insights into how Allocetra™ demonstrated statistically significant and clinically meaningful improvements in pain reduction and function among patients with age-related osteoarthritis, a population representing a major unmet medical need and a growing billion-dollar market. He will also highlight the Company’s clinical roadmap, including the upcoming six-month data readout expected in November 2025 and the planned initiation of a Phase IIb trial in 2026, which are designed to further validate Allocetra™‘s potential as a transformative therapy for millions of KOA patients worldwide.
Geoffrey Dow, CEO of 60 Degrees Pharmaceuticals, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to discuss the Company’s mission to combat infectious diseases with innovative, small-molecule therapeutics. Dow highlights the potential of ARAKODA® (tafenoquine), an FDA-approved antimalarial developed with the U.S. Army, and its expanding commercial footprint in the U.S. He also outlines 60 Degrees Pharmaceuticals’ strategy to repurpose tafenoquine for other serious infectious diseases, including babesiosis-a growing tick-borne illness with tens of thousands of new U.S. cases annually. With two potentially pivotal clinical trials underway, a third study in the final planning stages, and a strong foundation of IP, regulatory experience, and institutional support, 60 Degrees Pharmaceuticals is advancing a cost-effective, scalable model for addressing unmet needs in global infectious disease treatment.
ENLV and SXTP are clients of RedChip Companies. Please read our full disclosure at https://www.redchip.com/legal/disclosures.
About Enlivex Therapeutics
Enlivex is a clinical stage macrophage reprogramming immunotherapy company developing Allocetra™, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution of life-threatening and life debilitating conditions. For more information, visit https://enlivex.com/.
60 Degrees Pharmaceuticals, Inc.
60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases that affect the lives of millions of people. 60 Degrees Pharmaceuticals, Inc. achieved FDA approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention, in 2018. 60 Degrees Pharmaceuticals, Inc. also collaborates with prominent research organizations in the U.S., Australia, and Singapore. The 60 Degrees Pharmaceuticals, Inc. mission has been supported through in-kind funding from the U.S. Department of Defense and private institutional investors including Knight Therapeutics Inc., a Canadian-based pan-American specialty pharmaceutical company. 60 Degrees Pharmaceuticals, Inc. is headquartered in Washington D.C., with a majority-owned subsidiary in Australia. Learn more at www.60degreespharma.com. The statements contained herein may include prospects, statements of future expectations and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties. Actual results, performance or events may differ materially from those expressed or implied in such forward-looking statements.
About RedChip Companies
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 33 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. RedChip also offers RedChat™, a proprietary AI-powered chatbot that analyzes SEC filings and corporate disclosures for all Nasdaq and NYSE-listed companies, giving investors instant, on-demand insights.
To learn more about RedChip’s products and services, please visit:
https://www.redchip.com/corporate/investor_relations
“Discovering Tomorrow’s Blue Chips Today”™
Follow RedChip on LinkedIn: https://www.linkedin.com/company/redchip/
Follow RedChip on Facebook: https://www.facebook.com/RedChipCompanies
Follow RedChip on Instagram: https://www.instagram.com/redchipcompanies/
Follow RedChip on Twitter: https://twitter.com/RedChip
Follow RedChip on YouTube: https://www.youtube.com/@redchip
Follow RedChip on Rumble: https://rumble.com/c/c-3068340
Subscribe to our Mailing List: https://www.redchip.com/newsletter/latest
Contact:
Dave Gentry
RedChip Companies Inc.
1-407-644-4256
info@redchip.com
–END–
SOURCE: RedChip Companies, Inc.
View the original press release on ACCESS Newswire
